Abstract: A composition comprising a cell or a population thereof, wherein the cell comprises a polynucleotide encoding an antibody or a fragment thereof that binds CD269 (BCMA), wherein the binding to CD269 (BCMA) disrupts the interaction between CD269 and its native ligands (BAFF and APRIL). Also disclosed is treatment of plasma cell-mediated diseases such as multiple myeloma and autoimmune diseases.

Abstract: A composition comprising a cell or a population thereof, wherein the cell comprises a polynucleotide encoding an antibody or a fragment thereof that binds CD269 (BCMA), wherein the binding to CD269 (BCMA) disrupts the interaction between CD269 and its native ligands (BAFF and APRIL). Also disclosed is treatment of plasma cell-mediated diseases such as multiple myeloma and autoimmune diseases.

Abstract: The invention relates to antibodies or antibody fragments that bind CD269 (BCMA), thereby disrupting the interaction between CD269 and its native ligands (BAFF and APRIL), and their use in the treatment of plasma cell-mediated diseases such as multiple myeloma and autoimmune diseases.

Abstract: The invention relates to antibodies or antibody fragments that bind CD269 (BCMA), thereby disrupting the interaction between CD269 and its native ligands (BAFF and APRIL), and their use in the treatment of plasma cell-mediated diseases such as multiple myeloma and autoimmune diseases.

Abstract: The invention relates to antibodies or antibody fragments that bind CD269 (BCMA), thereby disrupting the interaction between CD269 and its native ligands (BAFF and APRIL), and their use in the treatment of plasma cell-mediated diseases such as multiple myeloma and autoimmune diseases.

Abstract: The invention relates to antibodies or antibody fragments that bind CD269 (BCMA), thereby disrupting the interaction between CD269 and its native ligands (BAFF and APRIL), and their use in the treatment of plasma cell-mediated diseases such as multiple myeloma and autoimmune diseases.

Abstract: A harness making device having at least two receiving sections, a pivoting gripping device, a cable preparation device, and a cable transfer. Each receiving section is utilized for receiving a connection mechanism. The connection mechanism, in each case, connects an end portion of a cable to a connector. The gripping device is located in a fixed position between the at least two receiving sections, and is constructed to guide the end portion of the cable to the connection mechanism. Additionally, a cable preparation device is positioned to prepare a cable loop with the cable. The cable transfer, which is constructed to receive the at least one cable from the cable preparation device, positions the cable to the pivoting gripping device.

Abstract: A harness making device having at least two receiving sections, a pivoting gripping device, a cable preparation device, and a cable transfer. Each receiving section is utilized for receiving a connection mechanism. The connection mechanism, in each case, connects an end portion of a cable to a connector. The gripping device is located in a fixed position between the at least two receiving sections, and is constructed to guide the end portion of the cable to the connection mechanism. Additionally, a cable preparation device is positioned to prepare a cable loop with the cable. The cable transfer, which is constructed to receive the at least one cable from the cable preparation device, positions the cable to the pivoting gripping device.

Abstract: The invention relates to monoclonal antibodies against leucocyte-specific G protein-coupled receptors (L-GCR). These antibodies are obtainable by the following steps: (a) introduction of an L-GCR-coding nucleic acid into cells and expression of L-GCR, (b) immunization of an animal with L-GCR-expressing cells of (a), and (c) fusion of spleen cells from the immunized animal of (b) with myeloma cells and production of monoclonal L-GCR antibody-producing hybridoma cells. Furthermore, the invention relates to processes for the production of such antibodies, their use and kits containing the same. In addition, the invention concerns a process for the production of monoclonal GCR antibodies.